Galera Therapeutics (NASDAQ:GRTX) reported quarterly losses of $(0.88) per share. This is a 17.33 percent decrease over losses of $(0.75) per share from the same period last year.
Related Posts
Canaccord Genuity Maintains Hold on Freshworks, Raises Price Target to $17
Canaccord Genuity analyst David Hynes maintains Freshworks (NASDAQ:FRSH) with a Hold and raises the price target from $15 to $17.
XPO Logistics Analyst Slashes Price Target By 34%; Says Brokerage Separation Simplifies Story At XPO
Raymond James analyst Patrick Tyler Brown reiterated an Outperform rating on the shares of XPO Logistics Inc (NYSE:XPO) and lowered the price…
Morgan Stanley Maintains Equal-Weight on Bloomin Brands, Lowers Price Target to $21
Morgan Stanley analyst John Glass maintains Bloomin Brands (NASDAQ:BLMN) with a Equal-Weight and lowers the price target from $26 to $21.